Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors
Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for...
Ausführliche Beschreibung
Autor*in: |
Stang, K. M [verfasserIn] Alite, F. [verfasserIn] Small, C. [verfasserIn] Mar, H. [verfasserIn] Adams, W. H [verfasserIn] Sethi, A. [verfasserIn] Emami, B. [verfasserIn] Harkenrider, Matthew M [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2016 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Journal of radiation oncology - Berlin : Springer, 2012, 5(2016), 4 vom: 17. Aug., Seite 371-377 |
---|---|
Übergeordnetes Werk: |
volume:5 ; year:2016 ; number:4 ; day:17 ; month:08 ; pages:371-377 |
Links: |
---|
DOI / URN: |
10.1007/s13566-016-0272-5 |
---|
Katalog-ID: |
SPR031812031 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR031812031 | ||
003 | DE-627 | ||
005 | 20230519141840.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13566-016-0272-5 |2 doi | |
035 | |a (DE-627)SPR031812031 | ||
035 | |a (SPR)s13566-016-0272-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Stang, K. M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. | ||
650 | 4 | |a Lung cancer |7 (dpeaa)DE-He213 | |
650 | 4 | |a Central |7 (dpeaa)DE-He213 | |
650 | 4 | |a SBRT |7 (dpeaa)DE-He213 | |
650 | 4 | |a Esophagitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Esophageal toxicity |7 (dpeaa)DE-He213 | |
700 | 1 | |a Alite, F. |e verfasserin |4 aut | |
700 | 1 | |a Small, C. |e verfasserin |4 aut | |
700 | 1 | |a Mar, H. |e verfasserin |4 aut | |
700 | 1 | |a Adams, W. H |e verfasserin |4 aut | |
700 | 1 | |a Sethi, A. |e verfasserin |4 aut | |
700 | 1 | |a Emami, B. |e verfasserin |4 aut | |
700 | 1 | |a Harkenrider, Matthew M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of radiation oncology |d Berlin : Springer, 2012 |g 5(2016), 4 vom: 17. Aug., Seite 371-377 |w (DE-627)718611233 |w (DE-600)2660511-9 |x 1948-7908 |7 nnns |
773 | 1 | 8 | |g volume:5 |g year:2016 |g number:4 |g day:17 |g month:08 |g pages:371-377 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13566-016-0272-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2472 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 5 |j 2016 |e 4 |b 17 |c 08 |h 371-377 |
author_variant |
k m s km kms f a fa c s cs h m hm w h a wh wha a s as b e be m m h mm mmh |
---|---|
matchkey_str |
article:19487908:2016----::oepeitroeohgatxctwtseetcibdrdainh |
hierarchy_sort_str |
2016 |
publishDate |
2016 |
allfields |
10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377 |
spelling |
10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377 |
allfields_unstemmed |
10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377 |
allfieldsGer |
10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377 |
allfieldsSound |
10.1007/s13566-016-0272-5 doi (DE-627)SPR031812031 (SPR)s13566-016-0272-5-e DE-627 ger DE-627 rakwb eng 610 ASE Stang, K. M verfasserin aut Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 Alite, F. verfasserin aut Small, C. verfasserin aut Mar, H. verfasserin aut Adams, W. H verfasserin aut Sethi, A. verfasserin aut Emami, B. verfasserin aut Harkenrider, Matthew M verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2016), 4 vom: 17. Aug., Seite 371-377 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2016 number:4 day:17 month:08 pages:371-377 https://dx.doi.org/10.1007/s13566-016-0272-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2016 4 17 08 371-377 |
language |
English |
source |
Enthalten in Journal of radiation oncology 5(2016), 4 vom: 17. Aug., Seite 371-377 volume:5 year:2016 number:4 day:17 month:08 pages:371-377 |
sourceStr |
Enthalten in Journal of radiation oncology 5(2016), 4 vom: 17. Aug., Seite 371-377 volume:5 year:2016 number:4 day:17 month:08 pages:371-377 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Lung cancer Central SBRT Esophagitis Esophageal toxicity |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Journal of radiation oncology |
authorswithroles_txt_mv |
Stang, K. M @@aut@@ Alite, F. @@aut@@ Small, C. @@aut@@ Mar, H. @@aut@@ Adams, W. H @@aut@@ Sethi, A. @@aut@@ Emami, B. @@aut@@ Harkenrider, Matthew M @@aut@@ |
publishDateDaySort_date |
2016-08-17T00:00:00Z |
hierarchy_top_id |
718611233 |
dewey-sort |
3610 |
id |
SPR031812031 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812031</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-016-0272-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812031</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-016-0272-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stang, K. M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SBRT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophagitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophageal toxicity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alite, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Small, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mar, H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adams, W. H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sethi, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emami, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harkenrider, Matthew M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">5(2016), 4 vom: 17. Aug., Seite 371-377</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:4</subfield><subfield code="g">day:17</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:371-377</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-016-0272-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2016</subfield><subfield code="e">4</subfield><subfield code="b">17</subfield><subfield code="c">08</subfield><subfield code="h">371-377</subfield></datafield></record></collection>
|
author |
Stang, K. M |
spellingShingle |
Stang, K. M ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors |
authorStr |
Stang, K. M |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)718611233 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1948-7908 |
topic_title |
610 ASE Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors Lung cancer (dpeaa)DE-He213 Central (dpeaa)DE-He213 SBRT (dpeaa)DE-He213 Esophagitis (dpeaa)DE-He213 Esophageal toxicity (dpeaa)DE-He213 |
topic |
ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity |
topic_unstemmed |
ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity |
topic_browse |
ddc 610 misc Lung cancer misc Central misc SBRT misc Esophagitis misc Esophageal toxicity |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal of radiation oncology |
hierarchy_parent_id |
718611233 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Journal of radiation oncology |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)718611233 (DE-600)2660511-9 |
title |
Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors |
ctrlnum |
(DE-627)SPR031812031 (SPR)s13566-016-0272-5-e |
title_full |
Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors |
author_sort |
Stang, K. M |
journal |
Journal of radiation oncology |
journalStr |
Journal of radiation oncology |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2016 |
contenttype_str_mv |
txt |
container_start_page |
371 |
author_browse |
Stang, K. M Alite, F. Small, C. Mar, H. Adams, W. H Sethi, A. Emami, B. Harkenrider, Matthew M |
container_volume |
5 |
class |
610 ASE |
format_se |
Elektronische Aufsätze |
author-letter |
Stang, K. M |
doi_str_mv |
10.1007/s13566-016-0272-5 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors |
title_auth |
Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors |
abstract |
Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. |
abstractGer |
Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. |
abstract_unstemmed |
Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
container_issue |
4 |
title_short |
Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors |
url |
https://dx.doi.org/10.1007/s13566-016-0272-5 |
remote_bool |
true |
author2 |
Alite, F. Small, C. Mar, H. Adams, W. H Sethi, A. Emami, B. Harkenrider, Matthew M |
author2Str |
Alite, F. Small, C. Mar, H. Adams, W. H Sethi, A. Emami, B. Harkenrider, Matthew M |
ppnlink |
718611233 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s13566-016-0272-5 |
up_date |
2024-07-04T01:20:56.876Z |
_version_ |
1803609499899002880 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031812031</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-016-0272-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031812031</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-016-0272-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stang, K. M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel predictors of esophageal toxicity with stereotactic body radiation therapy for central lung tumors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose The aim of this study is to report on clinical and dosimetric endpoints for development of esophagus toxicity (ET) in patients treated with thoracic stereotactic body radiation therapy (SBRT). Methods and materials One hundred thirty-one patients were treated from 2006 to 2014 with SBRT for primary, recurrent, and metastatic lung tumors. Thirty-four had central lesions. We collected esophageal dosimetric data including Dmax, D1cc, D5cc, and D10cc. We recorded the percent circumferential luminal overlap at 10 Gy intervals from 10 Gy to Dmax, as well as at 24, 39, and 50 Gy, by dividing the extent of overlapping isodose by total esophagus luminal circumference (calculated by 2π√($ a^{2} $ + $ b^{2} $/2)). Results Of 34 patients included for analysis, 9 had ET and 2 of which had high-grade ET. The mean axial percent esophagus encompassed by 24, 39, and 50 Gy isodose lines of patients with ET vs. no ET was 38.9 vs. 11.5 %, 8.8 vs. 2.3 %, and 5.7 vs. 0.5 % (p = 0.04, 0.16, 0.13, respectively). Mean maximum point dose, D1cc and D5cc for patients with ET vs. those without was 31.2 Gy vs. 18.2 Gy, 25.5 Gy vs. 14.1 Gy, 19.6 Gy vs. 10.0 Gy (p = 0.045, 0.067, 0.071, respectively). Multiple treatment sites and previous thoracic radiation were significantly associated with ET. Conclusions Previous thoracic RT, multiple-site irradiation, and percent esophageal overlap with 39 and 50 Gy isodose lines were most significantly associated with ET. These predictive factors can risk stratify SBRT patients for ET, and the dosimetric factors should be considered in treatment planning to decrease the risk of ET.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SBRT</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophagitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esophageal toxicity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alite, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Small, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mar, H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adams, W. H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sethi, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emami, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harkenrider, Matthew M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">5(2016), 4 vom: 17. Aug., Seite 371-377</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:4</subfield><subfield code="g">day:17</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:371-377</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-016-0272-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2016</subfield><subfield code="e">4</subfield><subfield code="b">17</subfield><subfield code="c">08</subfield><subfield code="h">371-377</subfield></datafield></record></collection>
|
score |
7.3992853 |